Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Part D Price Negotiation Provision In House Reform Bill Missing Its Teeth?

Executive Summary

The House health care reform bill passed by the Energy and Commerce Committee directs HHS to negotiate drug prices directly with manufacturers for the Medicare Part D program, but it does not authorize HHS to establish a national formulary

You may also be interested in...



HHS Envisions Drug Price Arbitration For Part D

Approaches for HHS to become involved in drug price negotiations between Medicare Part D plan sponsors and manufacturers were outlined by HHS Assistant Secretary for Planning and Evaluation Richard Frank at a policy conference, although current law would need to be revised to allow it.

Merged House Bill Seeks More Part D Savings, Broader Medicaid Expansion

The health care reform bill unveiled by the House leadership Oct. 29 seeks increased drug savings for the Medicare Part D program through mandated rebates for products provided to low-income beneficiaries and by requiring HHS to negotiate drug pricing directly with manufacturers

Merged House Bill Seeks More Part D Savings, Broader Medicaid Expansion

The health care reform bill unveiled by the House leadership Oct. 29 seeks increased drug savings for the Medicare Part D program through mandated rebates for products provided to low-income beneficiaries and by requiring HHS to negotiate drug pricing directly with manufacturers

Topics

UsernamePublicRestriction

Register

PS142351

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel